Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.57 million shares were traded. FMS stock price reached its highest trading level at $23.54 during the session, while it also had its lowest trading level at $23.31.
Ratios:
Our goal is to gain a better understanding of FMS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.82. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.81 whereas as Long-Term Debt/Eq ratio is at 0.72.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FMS now has a Market Capitalization of 13553335296 and an Enterprise Value of 16961728512. As of this moment, Fresenius’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.97, and their Forward P/E ratio for the next fiscal year is 9.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 0.89. Its current Enterprise Value per Revenue stands at 0.864 whereas that against EBITDA is 6.916.
Stock Price History:
The Beta on a monthly basis for FMS is 0.89, which has changed by -0.011416495 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, FMS has reached a high of $30.46, while it has fallen to a 52-week low of $22.05. The 50-Day Moving Average of the stock is -6.93%, while the 200-Day Moving Average is calculated to be -9.15%.
Shares Statistics:
The stock has traded on average 416.28K shares per day over the past 3-months and 462970 shares per day over the last 10 days, according to various share statistics. A total of 579.70M shares are outstanding, with a floating share count of 579.27M. Insiders hold about 0.07% of the company’s shares, while institutions hold 6.23% stake in the company. Shares short for FMS as of 1764288000 were 766762 with a Short Ratio of 1.82, compared to 1761868800 on 1661941.
Dividends & Splits
In the trailing 12 months, FMS’s forward annual dividend rate was 1.44, compared to 0.81 this year. Against a Trailing Annual Dividend Yield of 0.061591107. The stock’s 5-year Average Dividend Yield is 1.3. The current Payout Ratio is 57.49% for FMS, which recently paid a dividend on 2025-05-23 with an ex-dividend date of 2025-05-23. Stock splits for the company last occurred on 2012-12-04 when the company split stock in a 2:1 ratio.
Earnings Estimates
The performance of Fresenius Medical Care AG ADR (FMS) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.49, with high estimates of $0.49 and low estimates of $0.49.
Analysts are recommending an EPS of between $3.92 and $1.83 for the fiscal current year, implying an average EPS of $2.6. EPS for the following year is $2.94, with 6.0 analysts recommending between $4.63 and $2.0.
Revenue Estimates
5 analysts predict $4.76B in revenue for. The current quarter. It ranges from a high estimate of $5.15B to a low estimate of $3.92B. As of. The current estimate, Fresenius Medical Care AG ADR’s year-ago sales were $5.08BFor the next quarter, 5 analysts are estimating revenue of $4.97B. There is a high estimate of $5.01B for the next quarter, whereas the lowest estimate is $4.94B.
A total of 15 analysts have provided revenue estimates for FMS’s current fiscal year. The highest revenue estimate was $19.79B, while the lowest revenue estimate was $19.2B, resulting in an average revenue estimate of $19.55B. In the same quarter a year ago, actual revenue was $19.34BBased on 17 analysts’ estimates, the company’s revenue will be $20.15B in the next fiscal year. The high estimate is $20.78B and the low estimate is $19.68B.
